ARch Biopartners (QB) Aktie - ACHFF

ARch Biopartners Inc (QB) (ACHFF) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

0,5479

( - )

Gebot

0,5401

Fragen

0,5598

Volumen

0,00 Tagesbereich 0,00

0,2881 52-Wochen-Bereich 1,33

Marktkapitalisierung

37,221M

Handelsende

0,5479

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

US$ 0

Ausgegebene Aktien

67.933.289

Dividendenrendite (LTM)

Kurs-Gewinn-Verhältnis

-21,86

Gewinn pro Aktie (EPS)

-0,04

Erlöse (LTM)

158,08k

Nettogewinn (LTM)

-2,78M

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experience... Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada. Mehr anzeigen

Sektor

Healthcare

Branche

Biotechnology & Life Sciences

Website

www.archbiopartners.com

Hauptsitz

Toronto, Canada

Gegründet

ARch Biopartners Inc (QB) is listed in the Healthcare sector of the OTC Markets with ticker ACHFF. The last closing price for ARch Biopartners (QB) was US$0,55. Over the last year, ARch Biopartners (QB) shares have traded in a share price range of US$ 0,2881 to US$ 1,33.

ARch Biopartners (QB) currently has 67.933.289 shares in issue. The market capitalisation of ARch Biopartners (QB) is US$37,22 million. ARch Biopartners (QB) has a price to earnings ratio (PE ratio) of -21.86.

Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans

TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF...

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH...

Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI

TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

TORONTO, March 24, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH...

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH...

Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.1521	-21.7285714286	0.7	0.79	0.5475	39277	0.63953727	CS
4	0.19385	54.7521536506	0.35405	0.79	0.3033	38815	0.52698506	CS
12	0.13756	33.5234196033	0.41034	0.79	0.2881	30493	0.42041493	CS
26	-0.35054	-39.0165175193	0.89844	1.0165	0.2881	31929	0.54753531	CS
52	-0.7771	-58.6490566038	1.325	1.33	0.2881	32766	0.76276003	CS
156	-0.9621	-63.7152317881	1.51	1.88	0.2881	19810	0.98040581	CS
260	-0.5171	-48.5539906103	1.065	4.13	0.2881	17809	1.26446829	CS

ACHFF - Frequently Asked Questions (FAQ)

What is the current ARch Biopartners Inc (QB) share price?

The current share price of ARch Biopartners Inc (QB) is US$ 0,5479

How many ARch Biopartners Inc (QB) shares are in issue?

ARch Biopartners Inc (QB) has 67.933.289 shares in issue

What is the market cap of ARch Biopartners Inc (QB)?

The market capitalisation of ARch Biopartners Inc (QB) is USD 37,22M

What is the 1 year trading range for ARch Biopartners Inc (QB) share price?

ARch Biopartners Inc (QB) has traded in the range of US$ 0,2881 to US$ 1,33 during the past year

What is the PE ratio of ARch Biopartners Inc (QB)?

The price to earnings ratio of ARch Biopartners Inc (QB) is -21,86

What is the cash to sales ratio of ARch Biopartners Inc (QB)?

The cash to sales ratio of ARch Biopartners Inc (QB) is 391,63

What is the registered address of ARch Biopartners Inc (QB)?

The registered address for ARch Biopartners Inc (QB) is 545 King Street West, Toronto, Ontario, M5V 1M1

What is the ARch Biopartners Inc (QB) website address?

The website address for ARch Biopartners Inc (QB) is www.archbiopartners.com

Which industry sector does ARch Biopartners Inc (QB) operate in?

ARch Biopartners Inc (QB) operates in the Biotechnology & Life Sciences sector

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

ARch Biopartners Inc (QB) (ACHFF)

ARch Biopartners Inc (QB) (ACHFF) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über ARch Biopartners Inc (QB)

ACHFF Neueste Nachrichten

Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

ACHFF - Frequently Asked Questions (FAQ)

ACHFF Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen